Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: Implications for optimal dosing

Amy D. Klion, Jamie Robyn, Irina Maric, Weiming Fu, Laura Schmid, Steven Lemery, Pierre Noel, Melissa A. Law, Marilyn Hartsell, Cheryl Talar-Williams, Michael P. Fay, Cynthia E. Dunbar, Thomas B. Nutman

Research output: Contribution to journalArticle

82 Scopus citations

Fingerprint Dive into the research topics of 'Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: Implications for optimal dosing'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds